CS271011

CS271011 is a novel, liver-targeted thyroid hormone receptor-beta (THR-β) agonist developed by Chipscreen Biosciences for the treatment of lipid metabolism disorders, including metabolic dysfunction-associated steatohepatitis (MASH) and dyslipidemia. It is designed to selectively activate THR-β in hepatic tissue, thereby enhancing fatty acid oxidation and reducing liver fat content while minimizing the systemic side effects—such as cardiac arrhythmia and bone loss—typically associated with the activation of the THR-α isoform. In preclinical models, CS271011 demonstrated significant reductions in hepatic steatosis, triglycerides, and cholesterol levels, showing a favorable safety and efficacy profile compared to other THR-β agonists like resmetirom. It is currently undergoing early-stage clinical evaluation to assess its safety, tolerability, and pharmacokinetic properties in humans.